Paralytic ileus is a common intestinal dysfunction in critically ill patients. There are still no established the effective medications except correcting the primary causes and prokinetics trial which limited in efficacy and potential adverse events.
Prucalopride, a highly selective 5-HT4 receptor agonist, accelerates gastrointestinal transit which may reduce severity of ileus. Furthermore, there is no report of serious cardiac and neurological side effects. We aim to evaluate the efficacy of prucalopride as a prokinetic of choice on paralytic ileus in critically ill patients.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
62
1-2 mg once daily enteral feeding for 5 consecutive days
1/2-1 tablet once daily enteral feeding for 5 consecutive days
Faculty of Medicine, Prince of Songkla University
Songkhla, Thailand
RECRUITINGChange of maximum bowel diameter from baseline at 24 hours
measure on plain abdominal radiography by blinded radiologist
Time frame: after first dose intervention to next 24 hours
Change of maximum bowel diameter from baseline at 48 hours
measure on plain abdominal radiography by blinded radiologist
Time frame: after first dose intervention to next 48 hours
Change of maximum bowel diameter from baseline at 72 hours
measure on plain abdominal radiography by blinded radiologist
Time frame: after first dose intervention to next 72 hours
Change of maximum bowel diameter from baseline at 96 hours
measure on plain abdominal radiography by blinded radiologist
Time frame: after first dose intervention to next 96 hours
Change of maximum bowel diameter from baseline at 120 hours
measure on plain abdominal radiography by blinded radiologist
Time frame: after first dose intervention to next 120 hours
change of abdominal circumference from baseline at 24 hours
measured at umbilical level
Time frame: after first dose intervention to next 24 hours
change of abdominal circumference from baseline at 48 hours
measured at umbilical level
Time frame: after first dose intervention to next 48 hours
change of abdominal circumference from baseline at 72 hours
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
measured at umbilical level
Time frame: after first dose intervention to next 72 hours
change of abdominal circumference from baseline at 96 hours
measured at umbilical level
Time frame: after first dose intervention to next 96 hours
change of abdominal circumference from baseline at 120 hours
measured at umbilical level
Time frame: after first dose intervention to next 120 hours